Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Posts 2 Percent Revenue Growth for Q3

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported its third-quarter sales grew 2 percent year over year on soft demand from its research end markets and a 6 percent negative effect from foreign currency exchange.

The St. Louis-based chemicals and research products firm reported total sales of $639 million for the three months ended Sept. 30 compared to $626 million in sales for the third quarter of 2011. It fell short of Wall Street's consensus estimate of $657.6 million.

Sales for its Research Chemicals unit dropped 4 percent to $428 million from $446 million. On an organic basis, sales for the unit were up 1 percent.

Sales for the firm's SAFC business grew 17 percent to $211 million from $180 million. On an organic basis, sales for the unit were up 5 percent year over year.

"While we continue to experience soft demand in our Research business, our end markets have remained relatively stable from second quarter levels," Sigma-Aldrich President and CEO Rakesh Sachdev said in a statement. "We believe our recent initiatives, including new product launches and expansion in emerging markets, have set us up for improved performance in the coming quarters."

Sigma-Aldrich posted a profit of $112 million, or $.92 per share, compared to net income of $117 million, or $.95 per share, for Q3 2011. On an adjusted basis, EPS was $.94, matching analysts' consensus estimate.

The firm's R&D spending for the quarter was down around 6 percent to $17 million from $18 million, and its SG&A expenses declined 3 percent to $147 million from $152 million.

Sigma-Aldrich finished the quarter with $589 million in cash and cash equivalents.

The company said that it expects to report full-year 2012 organic revenue growth of around 3 percent, in line with its prior guidance of low- to mid-single digits. Foreign exchange rates are expected to reduce reportable sales for the year by around 3 percent. Its adjusted EPS is expected to between $3.80 and $3.90.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.